Brief: Tivdak Significantly Prolonged Overall Survival In Patients With Recurrent Or Metastatic Cervical Cancer Compared With Chemotherapy In Global Phase 3 Innovatv 301 Trial

Seagen

22/10/2023 17:02

Oct 22 (Reuters) - Genmab A/S  GMAB.CO :
    * TIVDAK® (TISOTUMAB VEDOTIN-TFTV) SIGNIFICANTLY PROLONGED
OVERALL
SURVIVAL IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL
CANCER COMPARED WITH CHEMOTHERAPY IN GLOBAL PHASE 3 INNOVATV 301
TRIAL
    * TIVDAK DEMONSTRATED SUPERIOR OVERALL SURVIVAL,
PROGRESSION-FREE
SURVIVAL AND OBJECTIVE RESPONSE RATE
    * GENMAB - RESULTS FROM INNOVATV 301 INTENDED TO SERVE AS
PIVOTAL
CONFIRMATORY TRIAL FOR U.S. ACCELERATED APPROVAL AND TO SUPPORT
GLOBAL REGULATORY APPLICATIONS

Source text for Eikon:  ID:nBw9wMRB6a 
Further company coverage:  GMAB.CO 

 ((Reuters.Briefs@thomsonreuters.com;))